Stay updated on Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.2 to v3.4.3 on the page.
    Difference
    0.1%
    Check dated 2026-03-11T16:24:34.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the government funding lapse notice as well as the prior Revision: v3.4.1 banner. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-11T05:51:34.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Adds a site-wide funding/operating status notice and updates versioning to v3.4.1, removing the previous v3.4.0 note.
    Difference
    0.5%
    Check dated 2026-02-04T04:43:09.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Show glossary option added and capitalization adjustments for labels such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', along with a revision tag to v3.4.0. Deletions remove lowercase variants and revert to an older revision label (v3.3.4).
    Difference
    0.2%
    Check dated 2026-01-28T02:28:31.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Revision: v3.3.4 was added and Revision: v3.3.3 was removed.
    Difference
    0.1%
    Check dated 2026-01-14T01:28:34.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Added Washington as a study location under the Locations section. The page revision was updated to v3.3.3 and the HHS Vulnerability Disclosure entry was removed.
    Difference
    0.2%
    Check dated 2025-12-23T09:00:46.000Z thumbnail image

Stay in the know with updates to Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page.